Want to join the conversation?
Gregg Gilbert with Deutsche Bank asks about REMICADE dynamics and the rate of erosion. $MRK said that on REMICADE, its strategy has been to try to hold on to as many existing patients that were currently treated. The company has done a good job with that. Most loss of revenue came from reference pricing due to lower prices from the biosimilars.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)